Difference between revisions of "Bupropion-clomipramine"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = clomipramine  
 
| to = clomipramine  
 
| stop =  
 
| stop =  
* '''Before day 1:''' Gradually reduce dosage of bupropion to a maximum of 150 mg/ day.
+
{{stopBupropion}}
* '''Day 1:''' Stop administration of bupropion
+
| start =  
| start =
+
{{Inc25p3d2}}
* '''Day 1-3:''' start administration of clomipramine the next day in a low dosage of 25-50 mg/day.
+
* Start administration of clomipramine in a low dosage of 25-50 mg/day.
* '''Day 4:''' increase dosage of clomipramine to 75 mg/day and continue slowly increasing the dosage depending on the condition of the patient.
+
 
 
| info =   
 
| info =   
 
* Bupropion slows the metabolism of clomipramine via CYP2D6.
 
* Bupropion slows the metabolism of clomipramine via CYP2D6.

Revision as of 11:00, 14 October 2015

Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion
Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine

Switch medication from bupropion to clomipramine.[1] [2]

Nietinrijdenbord.png Stop bupropion
  • Day 1: Stop bupropion.
  • bupropion can be stopped abruptly for every dosage.[3]
Eenrichtingbord.png Start clomipramine
  • Day 2: Start with normal dosage and increase with about 25% (up to 50%) every 3 days to target dose.
  • Start administration of clomipramine in a low dosage of 25-50 mg/day.
Infobord.png More information
  • Bupropion slows the metabolism of clomipramine via CYP2D6.
  • Caution is necessary at the start of administration of clomipramine.
  • The concomitant use of bupropion and tricyclic antidepressants (TCAs) may potentiate the risk of seizures. These agents are all epileptogenic and may have additive effects on the seizure threshold.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Multidisciplinair document Afbouwen Overige Antidepressiva 2023
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.